CERS1 (Ceramide Synthase 1, also known as CerS1) is a member of the ceramide synthase family that catalyzes the N-acylation of sphingoid bases to generate ceramides. In the brain, CERS1 is highly expressed in neurons and plays essential roles in lipid metabolism, myelin formation, and neuronal survival. CERS1 dysfunction is critically involved in Huntington's disease (HD) and other neurodegenerative conditions characterized by sphingolipid dysregulation.
| CERS1 Protein |
|---|
| Protein Name | CerS1 |
| Gene | [CERS1](/genes/cers1) |
| UniProt ID | [Q8WU39](https://www.uniprot.org/uniprot/Q8WU39) |
| Molecular Weight | 39 kDa (357 amino acids) |
| Subcellular Localization | Endoplasmic reticulum |
| Protein Family | Ceramide synthase (CerS) family |
| Aliases | LASS1, CerS1 |
CERS1 contains several functional features:
- Lag1p Domain: Conserved region essential for ceramide synthase activity
- HOX Domain: Homeobox domain involved in substrate specificity
- Multiple Transmembrane Regions: Required for ER localization and function
- N-terminal Region: Regulatory sequences controlling activity
CERS1 catalyzes the acylation of sphinganine (or sphingosine) to form ceramide:
- Substrate Specificity: Prefers C18:0 and C20:0 fatty acyl-CoA substrates
- Product Profile: Generates C18- and C20-ceramides
- Localization: Functions in the endoplasmic reticulum
- Sphingolipid Metabolism: Central player in sphingolipid biosynthetic pathway
- Myelin Formation: Essential for myelin lipid composition
- Neuronal Development: Regulates neurite outgrowth and differentiation
- Stress Response: Ceramide serves as second messenger in stress signaling
CERS1 is directly linked to HD pathogenesis:
- Loss of Function: CERS1 expression is reduced in HD patient brains and mouse models [1]
- Therapeutic Target: Increasing CERS1 improves neuronal survival in HD models
- Mechanism: Reduced C18-ceramide leads to impaired autophagy and increased vulnerability
In AD, ceramide metabolism is dysregulated:
- Elevated Ceramides: Total ceramide levels are increased in AD brains
- CERS1 Downregulation: Reduced CERS1 contributes to lipid raft alterations
- Aβ Interaction: Amyloid-beta affects ceramide metabolism
CERS1 involvement in PD:
- Dopaminergic Vulnerability: CERS1 may modulate sensitivity of dopaminergic neurons
- α-Synuclein Toxicity: Ceramide metabolism intersects with α-synuclein clearance
CERS1 mutations cause a form of neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder:
- Enzymatic Function: Loss of CERS1 leads to accumulation of lipopigments
- Childhood Neurodegeneration: Progressive neurodegeneration in affected individuals
- CERS1 Activators: Small molecules to increase CERS1 activity
- Exogenous C18-ceramide: Direct supplementation
- Gene Therapy: Viral delivery of CERS1
| Approach |
Stage |
Indication |
| CERS1 expression modulation |
Preclinical |
HD |
| Ceramide analog therapy |
Preclinical |
HD, AD |
| Lipid supplementation |
Clinical trials |
Various |
- Sphingomyelin Synthases: Downstream conversion to sphingomyelin
- Glucosylceramide Synthases: Channel to complex glycosphingolipids
- Ceramidases: Hydrolysis of ceramide to sphingosine
- Apoptosis: Ceramide is pro-apoptotic second messenger
- Autophagy: Ceramide induces autophagic flux
- ER Stress: Ceramide coordinates unfolded protein response
- Yu J, et al. (2020). CERS1 in neuronal ceroid lipofuscinosis. Neurobiol Aging 86: 1-10
- Eriksson IK, et al. (2015). CERS1 mutations cause neurodegeneration. Brain 138: 3168-3182
- Jenkins RW, et al. (2013). Ceramide synthases in brain function. J Lipid Res 54: 691-703
- Yu J, et al. (2020). CERS1 in neuronal ceroid lipofuscinosis. Neurobiol Aging 86: 1-10.
- Eriksson IK, et al. (2015). CERS1 mutations cause neurodegeneration. Brain 138: 3168-3182.
- Jenkins RW, et al. (2013). Ceramide synthases in brain function. J Lipid Res 54: 691-703.
- Costantini C, et al. (2018). CERS1 and sphingolipid metabolism in the brain. Prostaglandins Other Lipid Mediat 136: 55-63.